Biomarker Testing in Cancer

Biomarkers are genes, proteins, and other substances which can provide information about an individual’s cancer as each person has a unique pattern of biomarkers. They are also known as tumor markers. Some are cancer specific, whereas others may be associated with different cancer types. Some biomarkers provide diagnosis, some prognosis and some affect how certain cancer treatments work. Many different tumor markers have been characterized and are in clinical use.

Commonly tested Cancer Biomarkers with Prognostic/Predictive importance

Test CodeBiomarkerCancerImportance/Therapy
OG016IDH1 & 2AMLEnasidenib, Ivosidenib, Vorasidenib
OG032CEBPAAMLCEBPA mutations are associated with favourable prognosis in the absence of associated cytogenetic abnormalities
OG033NPM1AMLFavourable prognosis in the absence of a FLT3 internal tandem duplication
OG019PIK3CABreast CancerPI3K inhibitor; Alpelisib
OG035HER2 mutationsHer2+ Breast CancerHER2-positive patients carrying S310F, S310Y, R678Q, D769H, or I767M mutations are good candidates for anti-HER2 therapy. L755S or D769Y mutation also confer benefits when receiving Neratinib or Afatinib. Mutations L755S, V842I, K753I, or D769Y do not seem to benefit from Trastuzumab. Resistance to Lapatinib in patients with L755S, V842I, and K753I mutations
OG036HER2 Amplification (+ve/ -ve)Metastatic Breast CancerHer2 +ve -Aggressive cancer; Tucatinib (Tukysa), Trastuzumab (Herceptin) and  Capecitabine (Xeloda)
OG021ABL KINASE mutationsCMLResistance to BCR-ABL tyrosine kinase inhibitor (TKIs) Imatinib
OG022BCR/ABLCMLImatinib, Dasatinib, Nilotinib
OG015UGTA1CRC, Gastrointestinal cancersToxicity to Irinotecan therapy
OG014DPYDCRC, Head& Neck, Gastro-intestinal cancerToxicity to Fluorouracil/ 5FU therapy, capecitabine
OG037NRASCRC, Melanoma, Haemopoitic malignancies, Lung CancerTrametinib
OG038KITGIST, MelanomaImatinib, Sunitinib
OG016IDH1 & 2GliobastomaIDH mutations are diagnostic marker for differential diagnosis of low-grade glioma from reactive gliosis and other IDH-wild type tumour entities. First-line PCV in combination with radiotherapy
OG020TPMTLeukaemia, LymphomaHematopoietic toxicity
OG017EGFRLungPositive response to tyrosine kinase inhibitors (TKIs): Afatinib (Gilotrif), Dacomitinib (Vizimpro), Erlotinib (Tarceva), Gefitinib (Iressa), Osimertinib (Tagrisso)
OG039MET EXON 14 SKIPPINGLungMET inhibitor drug: Capmatinib or Tepotinib, TEPMETKO
OG010NTRK FUSIONLungEntrectinib and Larotrectinib.
OG010ALK FUSIONLungTyrosine kinase inhibitor (TKI) or ALK-inhibitor (Crizotinib (Xalkori) Ceritinib (Zykadia) Alectinib (Alecensa) Brigatinib (Alunbrig) Lorlatinib (Lorbrena))
OG010ROS1 FUSIONLungROS1 tyrosine kinase inhibitor (TKI) or ROS1 inhibitor (crizotinib or entrectinib)
OG010RET FUSIONLungSelpercatinib and pralsetinib (RET-inhibitors)
OG040KRASLung, CRC1. Sotorasib (FDA approvded) in G12C mutation in NSCLC. 2. In KRAS mutated CRC cases: poor response to EGFR-inhibitors & patients with a KRAS mutation or unknown KRAS status should not receive EGFR-inhibitors like Cetuximab or Panitumumab. 3. Patients with mutated or unknown KRAS or NRAS status should receive chemotherapy including FOLFOX, CAPOX, or FOLFIRI with or without bevacizumab
OG018BRAFLung, CRC, MelanomaBRAF inhibitors: Dabrafenib, Encorafenib,Vemurafenib
OG041TERTMelanomaLonger survival in patients with melanoma receiving BRAF/MEK-targeted therapies
OG042JAK2Myeloproliferative cancerRuxolitinib
OG012Homologous Recombination Repair (HRR) deficiency related mutationsBreast, Ovarian, ProstatePARP inhibitors (PARPis) Olaparib, Rucaparib and Niraparib
OG006Microsatellite Instability (MSI)CRCImmune checkpoint inhibitors
OG001/OG002BRCA 1/ 2 mutationsBreast CancerOlaparib and Talazoparib
OG008Tumour Mutation Load/BurdenNSCLC, urothelial carcinomaPembrolizumab

Who needs this test?

Treating oncologists may refer patients to develop treatment strategies that target, specific tumour genome mutations, allow follow up of disease and understand the appropriateness of future second line treatments

Why Bioserve - REPROCELL India?

  • Clinically relevant improvements and their interpretations and links to drug efficacy.
  • Recommendations for targeted therapies or possible resistance mechanisms, and the prognosis and current clinical trials.
  • High precision reporting with accuracy by ensuring all the quality requirements.
  • Quicker Turnaround time, Competitive pricing and detailed clinical interpretations and links to drug response/efficacy wherever possible.
  • The test has been validated in house and offers coverage range of 500-1000X.

Our Other Panels!

We offer several cancer panels depending upon the needs of the Oncologists, these include..

BRCA 1/2 Gene Testing

BRCA panel for testing mutations in BRCA1 and BRCA2 genes

Lung RNA Fusion Panel

Lung RNA fusion panel for detecting gene fusions in major driver genes

BRCA Extended Panel

Profiling of 15 genes associated with hereditary Breast and Ovarian cancer, pancreatic and prostate cancer

Hereditary Cancers panel

Profiling of >140 genes associated with inherited cancers